Physician practice patterns in holding inflammatory bowel disease medications due to COVID-19, in the SECURE-IBD Registry

Manasi Agrawal, Erica J. Brenner, Xian Zhang, Jean Frederic Colombel, Michael D. Kappelman, Ryan C. Ungaro, Richard B. Gearry, Gilaad G. Kalpan, Michele Kissous-Hunt, James D. Lewis, Siew C. Ng, Jean Francois Rahier, Walter Reinisch, Frank M. Ruemmele, Flavio Steinwurz, Fox E. Underwood

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Background: We aimed to describe physician practice patterns in holding or continuing IBD therapy in the setting of COVID-19 infection, using the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease [SECURE-IBD] registry. Methods: IBD medications that were stopped due to COVID-19 were recorded in the SECURE-IBD registry in addition to demographic and clinical data. We conducted descriptive analyses to understand characteristics associated with stopping IBD medications in response to active COVID-19 infection. Results: Of 1499 patients, IBD medications were stopped in 518 [34.6%] patients. On bivariate and multivariable analyses, a diagnosis of ulcerative colitis or IBD-unspecified was associated with a lower odds of stopping medication compared with Crohn's disease (adjusted odds ratio [aOR] 0.6, 95% confidence interval [CI] 0.48, 0.75). When evaluating specific medications, 5-aminosalicylic acid was more likely to be continued [p <0.001] whereas anti-tumour necrosis factor therapy and immunomodulator therapy were more likely to be stopped [global p <0.001]. Other demographic and clinical characteristics did not affect prescription patterns. Conclusions: IBD medications other than immunomodulators were continued in the majority of IBD patients with COVID-19, in the international SECURE-IBD registry. Future studies are needed to understand the impact of stopping or continuing IBD medications on IBD- and COVID-19 related outcomes.

Original languageEnglish
Pages (from-to)860-863
Number of pages4
JournalJournal of Crohn's and Colitis
Issue number5
StatePublished - 4 May 2021


  • Crohn's disease
  • IBD therapy
  • Inflammatory bowel disease
  • coronavirus disease 2019
  • ulcerative colitis


Dive into the research topics of 'Physician practice patterns in holding inflammatory bowel disease medications due to COVID-19, in the SECURE-IBD Registry'. Together they form a unique fingerprint.

Cite this